Business Context and Reporting Period
This Form 8-K was filed by Aclaris Therapeutics, Inc. on December 20, 2018, reporting an event that occurred on December 17, 2018. The company is incorporated in Delaware and identifies as an emerging growth company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance and personnel changes.
Material Changes
The material change reported is the planned departure of a senior executive:
- Christopher Powala, Chief Regulatory and Development Officer, notified the company of his intention to retire.
- The retirement is effective as of June 3, 2019.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on business performance, or discussion of risks and contingencies. The document is limited to the announcement of the officer's departure.
Investor Verification Checklist
- Confirm the timeline for the transition of the Chief Regulatory and Development Officer role.
- Verify if a successor has been appointed or if an interim arrangement is in place.
- Review subsequent filings for any impact on the company's regulatory development pipeline due to this leadership change.